Dr. Kira Holmström works as head of biomarker research at Herantis Pharma Plc, a pharma company based in Finland that is focused on disease-modifying therapies for neurodegeneration. The company is currently developing HER-096 as a novel disease-modifying therapy for Parkinson’s disease (PD). Dr. Holmström has a background in both academic research and industry in both Europe and the US, where she has been working on the molecular mechanisms of neurodegeneration for the past 15 years. She has a long-standing history of both laboratory and clinical research in neurodegenerative disorders, and in the past five years in the industry she has focused on developing translational biomarker strategies and analyses to support disease-modifying therapies for CNS disorders. Her focus areas have been neurological diseases such as PD, amyotrophic lateral sclerosis and rare neurological disorders.